Guardant Health price target raised to $75 from $65 at Canaccord

Canaccord analyst Kyle Mikson raised the firm’s price target on Guardant Health (GH) to $75 from $65 and keeps a Buy rating on the shares. The firm said its increase is driven by increased revenue growth and operating margin expansion in the out years of our 10-year DCF model. The company provided an overview of its unique technology based on epigenomics, including aspirations to integrate artificial intelligence (AI) and expand to non-cancer indications. Management also walked through each of the company’s business segments and commercial strategy.